Metabolism and Metabolomics of Liver in Health and Disease
Women and men have probably never been concerned as much by their health as during this COVID-19 pandemic. In this context, lifestyle habits continue to be promoted as allies for daily prevention against diseases. This is valid also for metabolic diseases, among which many affect the liver and are r...
Saved in:
HerausgeberIn: | |
---|---|
Sonstige: | |
Year of Publication: | 2021 |
Language: | English |
Physical Description: | 1 electronic resource (268 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993545792704498 |
---|---|
ctrlnum |
(CKB)5400000000040577 (oapen)https://directory.doabooks.org/handle/20.500.12854/68388 (EXLCZ)995400000000040577 |
collection |
bib_alma |
record_format |
marc |
spelling |
Wahli, Walter edt Metabolism and Metabolomics of Liver in Health and Disease Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021 1 electronic resource (268 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Women and men have probably never been concerned as much by their health as during this COVID-19 pandemic. In this context, lifestyle habits continue to be promoted as allies for daily prevention against diseases. This is valid also for metabolic diseases, among which many affect the liver and are risk factors for aggravating the disease course of COVID-19. In fact, liver diseases are currently a major global health problem. There is a huge range of liver diseases and non-alcoholic fatty liver disease (NAFLD) is the most common chronic hepatic condition, which in some patients progresses to cirrhosis and liver cancer. Currently, substantial efforts are being made to better understand NAFLD, especially, because there is no U.S. Food and Drug Administration (FDA)-approved pharmacological therapy. To explore this disease, metabolomics is the most recently developed omics technology after genomics, transcriptomics, and proteomics. Metabolomics is the large-scale analysis of molecules, known as metabolites that are intermediate or end products of metabolism found within cells, tissues, and biofluids. This technology has a very high potential to identify biomarker candidates for the future development of new therapeutics. The book features articles that address metabolomics technology and its use to document different liver functions and dysfunctions, with a major focus on NAFLD. English Medicine bicssc nonalcoholic fatty liver disease nonalcoholic steatohepatitis Fibrosis Liver biopsy Genomics Metabolomics Proteomics Transcriptomics nicotinamide NAFLD steatosis heat stress primary mouse hepatocytes metabolic profile GC-MS multivariate statistical analysis arachidonic acid docosahexaenoic acid inflammation fibrosis lipidomics mass spectrometry in vitro HepaRG sodium saccharin reference toxicants de novo lipogenesis carbohydrate response element-binding protein ChREBP diabetes glucose production glycogen glycolysis glycogen storage disease type I hexosamine pentose phosphate pathway acupuncture imflammation lipid metabolism oxidative stress metabolomics quantitative profiling 1H-NMR spectroscopy liver bile acids metabolomics rat plasma tandem mass spectrometry liquid chromatography acetaminophen hepatotoxicity biomarker premalignant alcoholic liver disease cholestasis cirrhosis NAFL NASH standard operating procedures urine blood feces tissue cells liver function nonalcoholic fatty liver liquid chromatography-mass spectrometry nuclear magnetic resonance spectroscopy metabolic pathway non-alcoholic fatty liver disease non-alcoholic steatohepatitis transcription factors metabolic stress lipid homeostasis glucose homeostasis 3-03943-635-X 3-03943-636-8 Guillou, Hervé edt Wahli, Walter oth Guillou, Hervé oth |
language |
English |
format |
eBook |
author2 |
Guillou, Hervé Wahli, Walter Guillou, Hervé |
author_facet |
Guillou, Hervé Wahli, Walter Guillou, Hervé |
author2_variant |
w w ww h g hg |
author2_role |
HerausgeberIn Sonstige Sonstige |
title |
Metabolism and Metabolomics of Liver in Health and Disease |
spellingShingle |
Metabolism and Metabolomics of Liver in Health and Disease |
title_full |
Metabolism and Metabolomics of Liver in Health and Disease |
title_fullStr |
Metabolism and Metabolomics of Liver in Health and Disease |
title_full_unstemmed |
Metabolism and Metabolomics of Liver in Health and Disease |
title_auth |
Metabolism and Metabolomics of Liver in Health and Disease |
title_new |
Metabolism and Metabolomics of Liver in Health and Disease |
title_sort |
metabolism and metabolomics of liver in health and disease |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2021 |
physical |
1 electronic resource (268 p.) |
isbn |
3-03943-635-X 3-03943-636-8 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT wahliwalter metabolismandmetabolomicsofliverinhealthanddisease AT guillouherve metabolismandmetabolomicsofliverinhealthanddisease |
status_str |
n |
ids_txt_mv |
(CKB)5400000000040577 (oapen)https://directory.doabooks.org/handle/20.500.12854/68388 (EXLCZ)995400000000040577 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Metabolism and Metabolomics of Liver in Health and Disease |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField |
_version_ |
1796651434974904320 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04797nam-a2201201z--4500</leader><controlfield tag="001">993545792704498</controlfield><controlfield tag="005">20231214133001.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202105s2021 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000040577</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/68388</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000040577</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Wahli, Walter</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Metabolism and Metabolomics of Liver in Health and Disease</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel, Switzerland</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2021</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (268 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Women and men have probably never been concerned as much by their health as during this COVID-19 pandemic. In this context, lifestyle habits continue to be promoted as allies for daily prevention against diseases. This is valid also for metabolic diseases, among which many affect the liver and are risk factors for aggravating the disease course of COVID-19. In fact, liver diseases are currently a major global health problem. There is a huge range of liver diseases and non-alcoholic fatty liver disease (NAFLD) is the most common chronic hepatic condition, which in some patients progresses to cirrhosis and liver cancer. Currently, substantial efforts are being made to better understand NAFLD, especially, because there is no U.S. Food and Drug Administration (FDA)-approved pharmacological therapy. To explore this disease, metabolomics is the most recently developed omics technology after genomics, transcriptomics, and proteomics. Metabolomics is the large-scale analysis of molecules, known as metabolites that are intermediate or end products of metabolism found within cells, tissues, and biofluids. This technology has a very high potential to identify biomarker candidates for the future development of new therapeutics. The book features articles that address metabolomics technology and its use to document different liver functions and dysfunctions, with a major focus on NAFLD.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nonalcoholic fatty liver disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nonalcoholic steatohepatitis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Fibrosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Liver biopsy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Genomics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Metabolomics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Proteomics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Transcriptomics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nicotinamide</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NAFLD</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">steatosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">heat stress</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">primary mouse hepatocytes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metabolic profile</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">GC-MS</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">multivariate statistical analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">arachidonic acid</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">docosahexaenoic acid</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inflammation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">fibrosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lipidomics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mass spectrometry</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">in vitro</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HepaRG</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sodium saccharin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">reference toxicants</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">de novo lipogenesis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">carbohydrate response element-binding protein</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ChREBP</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">diabetes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glucose production</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glycogen</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glycolysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glycogen storage disease type I</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hexosamine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pentose phosphate pathway</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">acupuncture</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">imflammation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lipid metabolism</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oxidative stress</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metabolomics quantitative profiling</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">1H-NMR spectroscopy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">liver</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bile acids</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metabolomics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">rat plasma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tandem mass spectrometry</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">liquid chromatography</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">acetaminophen</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hepatotoxicity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarker</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">premalignant</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">alcoholic liver disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cholestasis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cirrhosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NAFL</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NASH</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">standard operating procedures</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">urine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">blood</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">feces</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tissue</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">liver function</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nonalcoholic fatty liver</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">liquid chromatography-mass spectrometry</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nuclear magnetic resonance spectroscopy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metabolic pathway</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">non-alcoholic fatty liver disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">non-alcoholic steatohepatitis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">transcription factors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metabolic stress</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lipid homeostasis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glucose homeostasis</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03943-635-X</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03943-636-8</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guillou, Hervé</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wahli, Walter</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guillou, Hervé</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:39:09 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338020390004498&Force_direct=true</subfield><subfield code="Z">5338020390004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338020390004498</subfield></datafield></record></collection> |